ALSO NOTED: Glaxo passes on option for Exelixis drug; The Motley Fool likes Schering-Plough; and much more...

> Exelixis announced that GlaxoSmithKline has decided not to exercise its option to license XL647 for further development and commercialization. As a result, Exelixis retains the right to develop and commercialize XL647 either independently or in collaboration with third parties. Release 

> Schering-Plough has pulled its European application for the antibiotic garenoxacin mesylate, saying that it couldn't provide additional information requested by the EMEA in the time allowed. Schering-Plough bought the global rights to the drug from Toyama Chemical. Report

> The FDA will provide priority review status for BioMarin's Kuvan, an experimental therapy for a rare genetic metabolic condition. Release

> The Motley Fool finds that Schering-Plough's consistent successes make it a steady, if unspectacular, earner in the pharma world. Report

> The European Commission offers some tips for fostering a successful biotech sector. Report

And Finally… The number of West Nile disease cases in the U.S. has quadrupled in the past year in the U.S., raising the chances that it may soon become an epidemic. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.